Skip to main content

Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction

The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Blueprint insiders received substantial benefits as part of change of control arrangements and certain insiders may have had conflicts of interests.

We are investigating whether the transaction offering documents may have contained materially misleading information and/or omissions.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP                                     

Guri Ademi

Toll Free: (866) 264-3995

Fax: (414) 482-8001

Recent Quotes

View More
Symbol Price Change (%)
AMZN  215.35
+2.31 (1.08%)
AAPL  262.33
+10.04 (3.98%)
AMD  241.58
+8.50 (3.65%)
BAC  52.12
+0.84 (1.65%)
GOOG  256.79
+3.00 (1.18%)
META  730.35
+13.44 (1.87%)
MSFT  517.67
+4.09 (0.80%)
NVDA  183.65
+0.43 (0.23%)
ORCL  281.68
-9.63 (-3.31%)
TSLA  443.69
+4.38 (1.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.